Over the past 20 years, significant advances in the pharmacological management of FH have been made with the introduction of various treatment avenues, including high-potency statins, ezetimibe and PCSK9 inhibitors, showing remarkable results in HeFH [1,10]. This evidence concerns the gene PCSK9 and familial hyperaldosteronism.